1. Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis. (2nd December 2019) Authors: Teeple, Amanda; Muser, Erik Journal: Journal of medical economics Issue: Volume 22:Number 12(2020) Page Start: 1268 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗